Products & Innovation / CNSide
CNSide®
CNSide®, pronounced “see-inside,” is a cerebrospinal fluid assay platform for primary and metastatic CNS cancers. From one cerebrospinal fluid (CSF) sample, it detects and quantifies tumor cells and profiles the molecular targets that can help guide treatment.
One assay platform, multiple jobs.
CNSide® is a CLIA laboratory-developed test that does two things from the same spinal-fluid sample:
For a clinician, that changes what a CSF test can do: more sensitive detection than CSF cytology, a way to see whether treatment is working, and molecular targets that can change the therapy a patient receives.
Detection and monitoring
It captures and counts tumor cells in the CSF, giving a quantitative measure of disease that can be followed over time, not the yes-or-no answer of standard CSF cytology.
Biomarker characterization
Through a next-generation sequencing collaboration with Genomic Testing Cooperative, it profiles DNA and RNA across the tumor’s molecular targets, to help match patients to therapy.
From a CSF sample, CNSide® offers two tests that can be ordered individually or together:
CNSide® combines tumor cell enumeration with biomarker and genomic analysis to provide actionable information from a minimally invasive sample that can be collected longitudinally to monitor disease over time.
Test 1: Tumor cell detection and biomarker characterization
CNSide® captures and identifies tumor cells in the CSF, providing a quantitative tumor cell count rather than a binary positive or negative result.
Immunocytochemistry (ICC) and fluorescence in situ hybridization (FISH) characterize clinically relevant protein expression and genomic alterations in tumor cells identified in the CSF. Available Q4 2026.
Test 2: Genomic profiling
Next-generation sequencing (NGS) analyzes tumor-derived DNA and RNA across a broad panel of clinically relevant genes to identify molecular alterations that may help inform treatment decisions.
Why CNSide® exists.
Our VP of Research & Development on the gap CNSide® fills, how the assay works, and what a quantitative result changes for a clinician.
What the data shows in practice.
CNSide® fits across the care pathway: at diagnosis, in treatment decisions, and in response monitoring. Its primary focus is leptomeningeal metastases, with further applications in primary and other metastatic CNS cancers.
Adoption is measurable, too: a recent multicenter analysis covered 613 CNSide® assays ordered by 19 physicians across 5 institutions.1 Since 2020, more than 11,000 CNSide® tests have been performed at over 120 U.S. cancer institutions, supporting clinical decision-making across academic and community oncology practices nationwide.2
2.8x
2.8x the diagnostic sensitivity of standard CSF cytology.
90%
Influenced clinical management in more than 90% of leptomeningeal metastases cases.
60%
Identified HER2-positive tumor cells in the CSF of 60% of breast cancer patients whose primary tumors were HER2-negative.
Now part of the diagnostic standard.
The updated NCCN CNS Cancers Guidelines now include CSF circulating tumor cell analysis alongside tumor-derived DNA, expanding the leptomeningeal metastases (LM) diagnostic standard beyond cytology, so ordering CSF analysis like that of CNSide® now sits within guideline-supported practice.
1. FORESEE study (NCT05414123), presented at SNO 2024 and the 2025 SNO/ASCO CNS Metastases Conference.
2. These tests were performed by Biocept, Inc., CNSide’s original developer, prior to Cerenome’s (then Plus Therapeutics) acquisition of the CNSide platform on April 26, 2024.

“CNSide® is a more sensitive and definitive test for LM and has the potential to permit earlier diagnosis, manage our patients with more diagnostic precision, and hopefully improve therapeutic outcomes.”
Priya U. Kumthekar, MD
Neuro-Oncologist, Northwestern University
Availability & Access
Commercially available and reimbursed.
Evidence only matters if a clinician can act on it, which means being able to order the test and have a viable path to reimbursement. CNSide® provides both.
Map of 43 institutions that offer CNSide®. They are also listed after the map.
-
Allina Health
913 E 26th Street, Suite 304
Minneapolis, MN 55404Dr. Williams
-
Asthra Health
2811 Wilshire Blvd #790
Santa Monica, CA 90403Dr. Santosh Kesari
-
Atrium / Advocate Health
9201 University City Blvd
Charlotte, NC 28223Dr. Carol J. Farhangfar
-
Baylor Scott & White
300 University Blvd, Building A
Round Rock, TX 78665Dr. Levacic
Dr. Murillo -
Capital Health
1 Capital Way
Pennington, NJ 08534Dr. David Redjal
-
Clearview Cancer
3601 CCI Drive NW
Huntsville, AL 35805Dr. John F. Gleason Jr
-
Cleveland Clinic Ohio
10201 Carnegie Ave
Cleveland, OH 44106Dr. Dhawan
Dr. Lucas
Dr. Torres-Trejo -
Columbia University
710 W 168th Street
New York, NY 10032Dr. Diaz Ordonez
Dr. Haggiagi
Dr. Pan -
CommonSpirit
605 Glenwood Drive, Suite 200
Chattanooga, TN 37404Dr. Rana
-
Georgetown
3800 Reservoir Rd NW
Washington, DC 20007Dr. Claudine Janet Diana Isaacs
-
Holy Cross Health
4725 N Federal Highway
Fort Lauderdale, FL 33308Dr. Azzi
Dr. Segota -
HonorHealth
3621 N Wells Fargo Ave
Scottsdale, AZ 85251Dr. Azadi
-
Houston Methodist
6565 Fannin St
Houston, TX 77030Dr. Michael Youssef
-
Huntsman Cancer Institute
1950 Circle of Hope
Salt Lake City, UT 84112Dr. Malani
-
Inova Cancer Center
8081 Innovation Park Dr
Fairfax, VA 22031Dr. Meaghan Roy-O'Reilly
Dr. Catherine Wood
Dr. Adam Cohen -
Kootenai Health
700 W Ironwood Drive, Suite 130
Coeur d’Alene, ID 83814Dr. Allen
-
Louisiana State University Health
433 Bolivar St
New Orleans, LA 70112-7021Dr. Yazmin Odia
-
LSU / LCMC Health
1111 Medical Center Blvd, Suite S-750
Marrero, LA 70072Dr. Odia
-
Mayo Clinic Arizona
5777 E Mayo Blvd
Phoenix, AZ 85054Dr. Shannon Ensign
-
Mayo Clinic Florida
4500 San Pablo Road
Jacksonville, FL 32224Dr. Cordova
-
Mayo Clinic Minnesota
200 First Street SW
Rochester, MN 55905Dr. Sener
-
New York University Langone Health
530 1st Ave, 10W
New York, NY 10061Dr. Jonathan Yang
Dr. Alexandra Gewirtz -
Northwestern Medicine – Chicago
675 N St Clair St, Suite 20-100
Chicago, IL 60611-5975 -
Northwestern Medicine – Warrenville
4405 Weaver Pkwy
Warrenville, IL 60555Dr. Robin Buerki
-
Providence St. Joe
501 S Buena Vista St
Burbank, CA 91505Dr. Tran
-
Providence St. Jude
2151 N Harbor Blvd, Suite 3100
Fullerton, CA 92835Dr. Jose Carrillo
-
Rutgers
210 Somerset Street, 14th Floor
New Brunswick, NJ 08901Dr. Shaikh
Dr. Vojnic -
Stanford Medicine
875 Blake Wilbur Dr, Clinic D, MC 6510
Stanford, CA 94305Dr. Seema Nagpal
Dr. Lawrence Recht
Dr. Toni Cao
Dr. David Rogawski
Dr. Kate Therkelsen -
Sutter Health
1580 Valencia St, Floor 6
San Francisco, CA 94110Dr. Sharma Akansksha
-
Texas Oncology – Houston Medical Center
1350 First Colony Blvd
Sugar Land, TX 77479Dr. Maria Morales
-
Texas Oncology – Sugar Land
1350 First Colony Blvd
Sugar Land, TX 77479Dr. Lee
-
The Queen’s Medical Center
1301 Punchbowl Street
Honolulu, HI 96813Dr. Hara
-
Trinity Health
44405 Woodward Ave, H35
Pontiac, MI 48341-2985Dr. Imlay
-
UC San Diego Health
3855 Health Sciences Drive
La Jolla, CA 92093Dr. David Piccioni
-
UH Seidman Cancer Center
11100 Euclid Ave
Cleveland, OH 44106Dr. Li Yi
-
University of Alabama at Birmingham
2000 6th Ave S, Floor 2
Birmingham, AL 35233Dr. Brown
Dr. Sizemore -
University of Michigan
1500 E Medical Center Drive, Floor 1
Ann Arbor, MI 48109-5902Dr. Fortunato
-
University of Rochester
90 Crittenden Blvd
Rochester, NY 14642Dr. Hemminger
-
UPMC
5150 Centre Ave
Pittsburgh, PA 15232Dr. Jan Drappatz
-
UT Health San Antonio
7979 Wurzbach Rd, 4th Floor
San Antonio, TX 78229Dr. Andrew Brenner
-
UW / Fred Hutchinson
1959 NE Pacific Street, Floor 7
Seattle, WA 98195Dr. Lanman
Dr. Venur -
VCU Health
417 N 11th Street
Richmond, VA 23219Dr. Stocksdale
-
Yale Medicine
5520 Park Ave
Trumbull, CT 06611Dr. Nicholas Blondin
A real accredited test.
CNSide® is a laboratory-developed test (LDT), developed by CNSide Diagnostics, LLC, and performed in a CLIA-licensed, CAP-accredited laboratory.
Its own billing code.
A dedicated AMA Proprietary Laboratory Analyses (PLA) code, 0640U, for the CNSide® tumor cell enumeration test, effective July 1, 2026.
Reimbursed and adopted.
CNSide® Diagnostics holds a Provider Transaction Access Number (PTAN), has established commercial payer coverage, and is already in clinical use at a growing number of centers.
© 2026 CNSide Diagnostics, LLC is a subsidiary of Cerenome, Inc. CNSide is a trademark of CNSide Diagnostics, LLC. All rights reserved.
How CNSide® advances treatment.
Within Cerenome’s platform, CNSide® does more than diagnose. It’s the assay used in the ReSPECT-LM clinical trial to measure tumor cells in the CSF, tracking how leptomeningeal metastases respond to the REYOBIQ™ investigational treatment. The same readout that guides a clinician’s decisions helps advance the therapeutics behind them.
Order CNSide®, view specimen requirements, and read full test details at cnside-dx.com.